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Abstract
The slow diffusion of empirically supported treatments and the rapid diffusion of treatments
lacking empirical support play a significant role in the quality gap in the care of people with
severe mental illnesses. Further, the rapid diffusion of treatments of low cost-effectiveness limits
the system's ability to provide the full gamut of high-value treatments available to treat this
vulnerable population. Using the case of schizophrenia as an illustrative case study, we review the
context in which these paradoxical patterns of diffusion have occurred and propose policy
solutions.
INTRODUCTION
Understanding and correcting anomalous patterns of diffusion of health care innovations is
key to improving the performance of the US health care system.1,2 Low rates of adoption of
empirically supported treatments –henceforth referred to as evidence-based practices, and
high rates of adoption of non evidence-based practices plague the care of people with mental
illnesses.3 We focus on people with severe and persistent mental illnesses (those with
schizophrenia, bipolar disorder, and severe forms of major depression and anxiety disorders)
because of their distinct needs and treatment circumstances in the US. Most people with
severe mental illnesses are cared for in the specialty mental health sector, and their mental
health and general health care is largely financed by public funds.4 In addition, evidence-
based psychosocial practices aimed at facilitating community integration and rehabilitation
are uniquely critical in the treatment of this population because of the significant functional
impairment associated with these illnesses.5
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Using the case of schizophrenia as an illustrative case study, we describe paradoxical
patterns of diffusion and review factors likely to be associated with these patterns. Because
current use offers a window into past patterns of diffusion, we assume that diffusion and use
patterns are manifestations of the same underlying phenomenon.6 We conclude with a
discussion of policy strategies aimed at correcting the diffusion paradox and improving care
of this vulnerable population. Our discussion of factors associated with diffusion of
treatments and of policy solutions applies to all people with severe mental illnesses (SMIs).
SIGNIFICANCE AND PATTERNS OF CARE OF SCHIZOPHRENIA
Although schizophrenia affects only 0.7% of the US population (2 million adults), it
accounts for 5% of all burden of disease in the US and other developed countries as a result
of its early age of onset (third decade or younger), chronic course, significant disability, and
premature mortality.7
The economic burden of schizophrenia is also significant. By 2002, the overall US cost of
the illness was estimated to be $63 billion: $23 for direct health care and $8 billion for non-
health care costs, and $32 billion in indirect costs associated with lost productivity,
premature mortality, and negative effects on family members.8 This represents nearly half
the US cost of diabetes in 2002 in spite of the fact that diabetes is at least six times more
prevalent than schizophrenia.9
THE DIFFUSION PARADOX IN THE CARE OF SCHIZOPHRENIA
Slow Diffusion of Evidence-based Practices
In the last two decades, basic and clinical research programs in schizophrenia have
significantly expanded the therapeutic arsenal and improved patients’ odds of leading fuller
lives.10 However, as in other areas of health care, some innovations have diffused very
slowly from experimental to routine care settings.11 The resulting underuse of evidence-
based practices (EBPs) has deprived scores of patients from potentially beneficial
interventions.12 The schizophrenia Patient Outcomes Research Team (PORT) study found
that in the late 1990s, adherence with recommended outpatient practices ranged between
10% and 46% for ten of eleven practices studied.13 Later studies have confirmed these
results.14
Supported employment, family psychoeducation, and other evidence-based psychosocial
practices used to treat schizophrenia are more likely to diffuse slowly and to be used less
frequently than pharmacological EBPs.15 Moreover, limited evidence suggests that use of
psychosocial EBPs is diminishing.16 A detailed discussion of underused EBPs is beyond this
paper's scope. However, two EBPs are noteworthy: clozapine because of its unique role in
the treatment of schizophrenia,17 and Supported Employment because of the importance of
employment facilitating the community integration of these individuals.18
Although clozapine is the only drug approved by the Food and Drug Administration (FDA)
for the management of treatment-resistant symptoms and recurrent suicidal behavior,19 its
use rates are far lower than the estimated need.20 Strikingly, its diffusion and use were not
boosted by the FDA approval in December 2002 of a second indication (see Exhibit 1).
Underuse of clozapine is likely to be related to its potential for serious hematological
adverse effects and mandatory blood tests instituted to monitor hematological indices.21
However, the substantial reduction of the drug's hematological risk as a result of the
monitoring program and higher clozapine use rates observed in countries with similar blood
test requirements as the US suggest that factors unrelated to the drug also contribute to
underuse.22
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Supported Employment is an evidence-based approach to securing and maintaining
competitive employment for people with schizophrenia and other SMIs.23 Most vocational
services offered in routine care are not empirically supported. It is then troubling that rates
of use of any vocational service in this population range between 0−23%, and only 5% of
people were found to receive Supported Employment in one study.24 As with clozapine, its
underuse is likely to be multi-factorial. Marshall and colleagues found that successful
implementation of Supported Employment was associated with leadership, and the
workforce's experience, training, and attitudes regarding the employability of people with
SMIs.25
Rapid Diffusion of Non Evidence-based Practices
The rapid diffusion of practices lacking empirical support is a matter of great public health
and policy concern because at worst their potential for harm exceeds their likely benefit and
at best their use represents an inefficient use of resources; as such, their use constitutes
overuse.26 An example of overuse in the care of people with schizophrenia is antipsychotic
polypharmacy, the practice of using two or more antipsychotics simultaneously. Although
this practice lacks empirical support, methodologically diverse US studies have found rates
as high as 50% and its use appears to be on the rise.27 Although its contributing factors are
not well understood, evidence suggests that physicians use antipsychotic polypharmacy in
lieu of clozapine for patients with treatment-resistant symptoms.28
Rapid Diffusion of Treatment Practices of Lower Value
To address rising health care costs, policymakers have focused their attention not only on
diffusion and use of treatments of proven effectiveness but cost-effectiveness as well.29
Peter Orzag, former director of the Congressional Budget Office, endorsed an expanded
definition of overuse which includes situations in “which the added costs of a more
expensive service did not exceed the added benefits it was expected to provide.”30 The rapid
diffusion of atypical antipsychotic drugs and rise to standard of care status is an example of
overuse defined in this manner (see Exhibit 2).31 With the exception of clozapine, initial
claims of superior efficacy relative to conventional antipsychotic drugs have not been borne
out.32 Further, branded atypical antipsychotics are far more costly, and based on recent
research, less cost-effective than conventional antipsychotics.33 Although valid concerns
about the methodological quality of the cost-effectiveness data have been raised by Richard
Frank and others, available evidence suggests that the market dominance of non-clozapine
atypical agents fits the expanded definition of overuse given above.34
The National Implementing Evidence-based Practices for Severe Mental Illness Project, an
Initiative to Increase EBP Adoption
The National Implementing Evidence-Based Practices for Severe Mental Illness Project (or
Implementing EBPs Project for short) has sought to promote the implementation of
underused EBPs for schizophrenia and other SMIs.35 Investigators developed
implementation toolkits and piloted the implementation of five psychosocial EBPs in eight
states.36 An indirect measure of the success of the Implementing EBPs Project is evidence
that states have steadily expanded their offering of the psychosocial practices promoted by
this initiative.37
FACTORS ASSOCIATED WITH THE DIFFUSION OF TREATMENTS
The rate at which treatment innovations spread through the health care system results from
the interplay of several factors. The diffusion literature distinguishes factors related to the
innovation (e.g., effectiveness, safety); patients (e.g., treatment preferences); clinicians
(attitudes and knowledge/competencies); and the system of care.38 System-level factors
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include all aspects of the environment where care occurs (e.g., financial policies,
regulations, structural and cultural characteristics of adopting organizations). In the US, the
system of care for people with schizophrenia and other SMIs is the publicly funded specialty
mental health sector. Public health programs play a crucial role in the financing, and to a
lesser extent, the delivery of health care. Additional public sector dollars fund key social
services for this population. These public programs operate in an environment characterized
by short term constraints and chronic resource limitations, and the delivery system is a
poorly coordinated web of public and private providers with few incentives to plan for the
long term.
In what follows we discuss factors amenable to public policies that are likely to have an
important role in the diffusion paradox in the care of people with schizophrenia.39
Financing of Care
We focus on Medicaid and Medicare although note that the Veterans Health Administration
and state and local governments also play a role financing the care of this population,
particularly veterans and uninsured people.40
Medicaid—Medicaid is the single largest payer for people with SMIs including those with
schizophrenia. An important trend in Medicaid has been the expansion of managed care
programs. For a large proportion of people with SMIs enrolled in these programs, non-
pharmacy benefits for mental health and substance abuse care (together known as behavioral
health care) are managed by Managed Behavioral Health Care Organizations in carve-out
arrangements.41
The net effects of managed care on the diffusion process are poorly understood. Managed
care is associated with greater use of ambulatory services, which in turn is associated with
greater use of medications to treat mental illnesses (henceforth referred to as psychotropic
drugs).42 However, managed care is also associated with greater use of management tools
aimed at curbing the use of expensive drugs.43 Further, the separation of behavioral health
and general health/pharmacy benefits that characterizes carve-out arrangements creates
incentives for a psychotropic drug-based approach to treatment and a reduction in the use of
psychosocial interventions.44 Overall, the evidence is mixed on the effects of Medicaid
managed care on quality of care for people with schizophrenia.45 The only published study
that has investigated the diffusion effects of carve-out arrangements found that they are
associated with an increase in the use of newer antidepressants but not of atypical
antipsychotics.46
Medicare—Many Medicare-covered disabled individuals, including people with
schizophrenia, are dually eligible for Medicaid coverage.47 With the implementation of the
Medicare Modernization Act (MMA) in 2006, pharmacy benefits of dually covered
individuals were transferred to Medicare, significantly expanding Medicare's role among
people with schizophrenia and other SMIs. Although little is known about the effects of
MMA on quality of care for this population, preliminary evidence suggests that access to
psychotropic drugs may be problematic.48
Regulatory Framework
Federal and state administrative practices—These practices aim to ensure the
quality of providers –through their accreditation, and of clinicians –through their licensing
and credentialing. Because accreditation allows payers to penalize providers that fail to meet
contractual performance standards, it could play a role in correcting the diffusion paradox in
the care of people with schizophrenia. Although performance measures of relevance to this
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population are available, the most widely used quality-monitoring tool (the Healthcare
Effectiveness Data and Information Set, HEDIS) does not contain any schizophrenia
measures.49 Similarly, oversight of quality of the mental health workforce by federal and
state agencies remains an underused regulatory tool.
Payer and health plan utilization management strategies—Although physician
profiling and other utilization management strategies could be used to promote high-quality
care, they have been primarily used to contain costs.50 Further, these strategies have been
exclusively used to modify psychotropic drug prescribing practices.51
Private Sector Initiatives
Private sector initiatives can influence the diffusion process. For example, advocacy by
patients and families accelerated the adoption of Assertive Community Treatment, and
advocates’ positive reviews of atypical antipsychotics may have contributed to the early
surge in their use.52 Sponsorship of academic activities and other pharmaceutical marketing
strategies increases demand for antidepressant and other prescription drugs.53 We are not
aware of similar empirical research for antipsychotic agents, but it is likely that aggressive
marketing of drugs still enjoying patent protection played a major role in the rapid diffusion
of non-clozapine atypical agents.54
Other Factors—The heterogeneous workforce involved in the care of people with
schizophrenia is generally lacking in the skills and competencies required to adopt EBPs and
deliver high-quality care to this population.55 Further, the challenging implementation and
uncertain sustainability of EBPs of higher complexity contribute to their underuse, and
despite the valuable implementation tools and evidence generated by the Implementing
EBPs Project, more research on the transport of EBPs to the real world is needed.56 In
addition, the variable quality and conflicting nature of available evidence on the
effectiveness and cost-effectiveness of treatments complicate decisions on which treatments
to fund and implement.57 Lastly, the insufficient computerization of the specialty mental
health sector may also contribute to the diffusion paradox because health information
technology can be used to monitor processes of care and promote evidence-based and high-
value care.58
POLICY STRATEGIES
Although the overriding objective of the strategies suggested below is to increase the use of
EBPs in the care of people with schizophrenia and other SMIs, some of them aim to
decrease the use of non evidence-based practices or increase the value (cost-effectiveness)
of care for this population.
Federal, state, and local governments are uniquely positioned to shape the financing and
organization as well as the content and quality of health and social services available to
people with schizophrenia. Exercising their leadership, these public entities could implement
a quality improvement agenda that among other things includes policies to influence
diffusion of treatments. High-level leadership will be crucial to advancing this agenda
because powerful institutions need to be mobilized, resources need to be reallocated, and
public-private partnerships need to be forged.59 Main targets for this high-level effort
include financial incentives, regulatory tools, quality of the workforce, and quality of the
evidence.
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Given Medicaid's central role in the financing of care for this population, the agency should
play a more active role in guiding treatment diffusion. In 2006 more than half of all state
Medicaid programs had adopted pay for performance approaches to promote high-value
care, and more states are expected to move in that direction.60 However, their target
populations and performance measures have largely excluded chronically ill adults and
people with SMIs.61 Following Medicare's lead, the federal government could pilot and
evaluate access, quality of care, and cost effects associated with the use of incentives to
promote high-value care for people with schizophrenia and other SMIs.62 Although tying
financial incentives to the preferred use of cost-effective treatments may encounter
resistance, there is growing support for initiatives that aim to maximize value in publicly
funded health care.63
State and regional Medicaid programs have two main policy levers to guide diffusion in
their fee-for-service programs. First, by modifying the pool of reimbursable services they
can promote the adoption of underused EBPs and discourage the use of non evidence-based
or lower-value treatment practices. Second, Medicaid programs can increase reimbursement
rates for EBPs and clarify existing coverage opportunities. Medicaid programs can also
guide diffusion in their managed care programs. First, they can increase capitation rates to
adequately reimburse high-value EBPs with high start-up or operating costs. Second, they
can incorporate expectations for evidence-based care into their procurement and contracting
processes, with performance provisions and other tools.
In addition, policymakers may consider making Managed Behavioral Health Care
Organizations financially responsible for psychotropic drug utilization. In doing so, they
would remove a financial incentive to delivering care that is largely based on psychotropic
drugs and is lacking in psychosocial treatments. Regardless of the financing mechanism,
contracts should promote long-term health planning and financial and administrative
coordination between providers of health and social services.
With regard to Medicare, in addition to the policy strategies outlined above for Medicaid, it
is critical to evaluate the quality of care effects of MMA for people with schizophrenia and
other SMIs.
Regulatory Tools
Accreditation and Licensing/Credentialing—The accreditation process for providers
serving people with schizophrenia and other SMIs needs to incorporate existing performance
measures for these illnesses. Further, to address the educational and training deficits of the
mental health workforce, policies should be enacted to standardize licensing and
credentialing requirements of clinicians and to ensure their uniform application across
disciplines, states, and health plans.
Utilization Management Strategies—Re-orienting the use of utilization management
strategies toward the attainment of quality goals would provide payers and health plans with
a powerful tool to correct the diffusion paradox in the care of people with schizophrenia. For
example, physician profiling and step therapy -the requirement that patients fail lower-cost
drugs before receiving coverage for higher-cost drugs, could be used to increase the
adoption of EBPs and to curb the use of non evidence-based as well as lower-value
practices.64
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Quality of the Workforce
The inadequacies of the mental health workforce call for a policy response that goes beyond
the changes in licensing and credentialing requirements mentioned above. A public-private
partnership that includes educational institutions and their accreditors should be established
with the goal of modernizing the curricula and training activities of mental health clinicians.
65 In the short and medium-term, the federal government should take a more active role in
training activities. For example, as recommended by Goldman and Azrin, the federal
government could develop a national multidisciplinary training program charged with
improving the quality of the workforce.66 Further, although several state mental health
agencies are developing training programs as part of their EBP implementation activities,
these state efforts should be expanded and sustained over time.67 Lastly, to address the
growing influence of pharmaceutical marketing on provider decision-making, the federal
government might consider public financing of academic detailing as well as mandating
public disclosure of pharmaceutical industry payments to physicians.
Quality of the Evidence—Correcting the diffusion paradox will require greater
governmental support for translational research aimed at bridging the science to services
gap.68 For example, the Substance Abuse and Mental Health Services Administration could
fund demonstrations focused on EBPs for schizophrenia to build upon and expand the
knowledge base generated by the Implementing EBPs Project.69
Although more research is needed to achieve better outcomes for people with schizophrenia,
it is equally important to better use existing knowledge. Similar to the National Institute for
Health and Clinical Excellence (NICE) in the UK, the Agency for Healthcare Research and
Quality (AHRQ) or a newly created entity could be charged with conducting appraisals of
the comparative effectiveness and cost effectiveness of treatments for schizophrenia.70 In
addition, AHRQ should sponsor research to develop and refine performance measures for
schizophrenia and other SMIs.71 Appraisals of the evidence and improved performance
measures would facilitate the implementation of payment methods aimed at improving
quality and value of health care. To address concerns of bias in pharmaceutical industry-
sponsored research, the source of the evidence used in the appraisals of the evidence should
be transparent.
Other Policy Strategies—At a time when the federal government is about to launch an
important initiative to promote the adoption of health information technology, greater use of
its considerable financial and administrative leverage is needed to expedite the adoption
process by providers serving people with SMIs.72 Strategies include building financial
incentives into contracts or tying provider accreditation to a minimal level of
computerization.
Lastly, engaging advocacy groups in initiatives aimed at correcting the diffusion paradox is
critical to ensuring their success.73 An important component of this effort involves
increasing advocates’ understanding of the variable quality of the empirical evidence and the
need to include cost and value of treatments in resource allocation decisions for publicly
funded health care.
Conclusions—Quality of care for people with schizophrenia and other SMIs is far from
optimal in the US. This troubling reality is in large measure a consequence of the slow
diffusion of EBPs and the rapid diffusion of non evidence-based or lower value practices.
We have reviewed factors that are likely to contribute to the diffusion paradox and have
proposed policy solutions with the potential to correct it.
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Daily dose units (DDUs) of clozapine per thousands of Medicaid enrollees, by clozapine
form, over time (1996 − 2005, selected quarters shown)
Source: Authors’ calculations from 1996−2005, fee-for-service Medicaid claims data.
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Exhibit 2
Percent* of persons with self-reported schizophrenia using each drug during the study year (n=237)
Atypical Antipsychotic Drug Percent with use in 1996/1997 Percent with use in 2004/2005 Growth in use (2004/2005 /
1996/1997)
Clozapine 3.9% (2.4) 4.8% (2.9) 21.7%
Olanzapine 12.1% (3.6) 35.0% (6.2) 189.9%
Quetiapine -- 14.4% (4.6) --
Risperidone 12.9% (4.9) 19.4% (4.6) 51.2%
Ziprasidone -- 10.1% (3.7) --
Aripiprazole -- 15.6% (4.4) --
Any 26.7% (6.6) 75.2% (5.0) 181.9%
Source: Authors’ calculations from 1996−2005 Medical Expenditure Panel Survey (pooled weights).
*
Percents reflect percentage of people reporting one or more filled prescriptions during the year (quetiapine, ziprasidone, and aripiprazole were not
available in 1996/1997). Persons may report use of more than one medication, so sum of percents is over 100%. Figures in parentheses are
linearized standard errors.
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